OD36

OD36 is a RIPK2 inhibitor with an IC50 of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. OD36 shows ALK2-directed activity with KDs of 37 nM[1][2].

Product Specifications

CAS Number

[1638644-62-8]

UNSPSC

12352005

Target

RIP kinase; TGF-β Receptor

Type

Reference compound

Related Pathways

Apoptosis; TGF-beta/Smad

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/od36.html

Purity

99.33

Solubility

DMSO : 33.33 mg/mL (ultrasonic)

Smiles

ClC1=CC(C2=C3N/C(C=CN3N=C2)=N/CCOCCO4)=CC4=C1

Molecular Formula

C16H15ClN4O2

Molecular Weight

330.77

References & Citations

[1]Gonzalo Sánchez-Duffhues, et al. Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells. JBMR Plus. 2019 Oct 7;3 (11) :e10230.|[2]Justine T Tigno-Aranjuez, et al. In vivo inhibition of RIPK2 kinase alleviates inflammatory disease. J Biol Chem. 2014 Oct 24;289 (43) :29651-64.|[3]Tigno-Aranjuez JT, et al. In vivo inhibition of RIPK2 kinase alleviates inflammatory disease. J Biol Chem. 2014 Oct 24;289 (43) :29651-64.